References
- 1. L. A. Torre, F. Bray, R. L. Siegel, J. Ferlay, J. Lortet-Tieulent and A. Jemal, Global cancer statistics, 2012, Ca-Cancer J. Clin.65 (2015) 87–108; https://doi.org/10.3322/caac.2126210.3322/caac.21262
- 2. C. A. Gabriel and S. M. Domchek, Breast cancer in young women, Breast Cancer Res. 12 (2010) 212–221; https://doi.org/10.1186/bcr264710.1186/bcr2647
- 3. G. Housman, S. Byler, S. Heerboth, K. Lapinska, M. Longacre, N. Snyder and S. Sarkar, Drug resistance in cancer: an overview, Cancers6 (2014) 1769–1792; https://doi.org/10.3390/cancers603176910.3390/cancers6031769
- 4. M. A. Aleskandarany, M. E. Vandenberghe, C. Marchiò, I. O. Ellis, A. Sapino and E. A. Rakha, Tumour heterogeneity of breast cancer: from morphology to personalized medicine, Pathobiology85 (2018) 23–34; https://doi.org/10.1159/00047785110.1159/000477851
- 5. S. Fais, G. Venturi and B. Gatenby, Microenvironmental acidosis in carcinogenesis and metastases: new strategies in prevention and therapy, Cancer Metastasis Rev.33 (2014) 1095–1108; https://doi.org/10.1007/s10555-014-9531-310.1007/s10555-014-9531-3
- 6. E. K. Rofstad, B. Mathiesen, K. Kindem and K. Galappathi, Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice, Cancer Res. 66 (2006) 6699–6707; https://doi.org/10.1158/0008-5472.can-06-098310.1158/0008-5472.CAN-06-0983
- 7. S. Taylor, E. P. Spugnini, Y. G. Assaraf, T. Azzarito, C. Rauch and S. Fais, Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach, Drug Resist. Updates23 (2015) 69–78; https://doi.org/10.1016/j.drup.2015.08.00410.1016/j.drup.2015.08.004
- 8. M. Bellone, A. Calcinotto, P. Filipazzi, L. Rivoltini, A. De Milito and S. Fais, The acidity of the tumor microenvironment is a mechanism of immune escape that can be overcome by proton pump inhibitors, OncoImmunology2 (2013) e22058; https://doi.org/10.4161/onci.2205810.4161/onci.22058
- 9. D. A. Loeffler, P. L. Juneau and G. H. Heppner, Natural killer-cell activity under conditions reflective of tumor micro-environment, Int. J. Cancer48 (1991) 895–899; https://doi.org/10.1002/ijc.291048061710.1002/ijc.2910480617
- 10. S. Fais, A. De Milito, H.You and W.Qin, Targeting vacuolar H+-ATPases as a new strategy against cancer, Cancer Res. 67 (2007) 10627–10630; https://doi.org/10.1158/0008-5472.CAN-07-180510.1158/0008-5472.CAN-07-1805
- 11. C. A. Stedman and M. L. Barclay, Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors, Aliment. Pharmacol. Ther.14 (2000) 963–978; https://doi.org/10.1046/j.1365-2036.2000.00788.x10.1046/j.1365-2036.2000.00788.x
- 12. K. Lindner, C. Borchardt, M. Schopp, A. Burgers, R. Hummel, C. Stock, D. J. Hussey and J. Haier, Proton pump inhibitors (PPIs) impact on tumour cell survival, metastatic potential and chemotherapy resistance, and affect expression of resistance-relevant miRNAs in esophageal cancer, Exp. Clin. Cancer Res.33 (2014) 73–85; https://doi.org/10.1186/s13046-014-0073-x10.1186/s13046-014-0073-x
- 13. J. Patlolla, Y. Zhang, Q. Li, V. Steele and C. Rao, Anti-carcinogenic properties of omeprazole against human colon cancer cells and azoxymethane-induced colonic aberrant crypt foci formation in rats, Int. J. Oncol.40 (2012) 170–175; https://doi.org/10.3892/ijo.2011.121410.3892/ijo.2011.1214
- 14. A. Udelnow, A. Kreyes, S. Ellinger, K. Landfester, P. Walther, T. Klapperstueck, J. Wohlrab, D. Henne-Bruns, U. Knippschild and P. Würl, Omeprazole inhibits proliferation and modulates autophagy in pancreatic cancer cells, Plos One6 (2011) e20143; https://doi.org/10.1371/journal.pone.002014310.1371/journal.pone.0020143
- 15. M. Yeo, D. K. Kim, Y. B. Kim, T. Y. Oh, J. E. Lee, S. W. Cho, H. C. Kim and K. B. Hahm, Selective induction of apoptosis with proton pump inhibitor in gastric cancer cells, Clin. Cancer Res.10 (2004) 8687–8696; https://doi.org/10.1158/1078-0432.CCR-04-106510.1158/1078-0432.CCR-04-1065
- 16. U. H. Jin, S. O. Lee, C. Pfent and S. Safe, The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis, BMC Cancer14 (2014) 498; https://doi.org/10.1186/1471-2407-14-49810.1186/1471-2407-14-498
- 17. Y. Shen, M. Chen, S. Huang and M. Zou, Pantoprazole inhibits human gastric adenocarcinoma SGC-7901 cells by downregulating the expression of pyruvate kinase M2, Oncol. Lett.11 (2016) 717–722; https://doi.org/10.3892/ol.2015.391210.3892/ol.2015.3912
- 18. X. Zeng, L. Liu, M. Zheng, H. Sun, J. Xiao, L. Lu, G. Huang, P. Chen, J. Zhang, F. Zhu, H. Li and Q. Duan, Pantoprazole, an FDA-approved proton-pump inhibitor, suppresses colorectal cancer growth by targeting T-cell-originated protein kinase, Oncotarget7 (2016) 22460–22473; https://doi.org/10.18632/oncotarget.798410.18632/oncotarget.7984
- 19. M. Chen, S. L. Huang, X. Q. Zhang, B. Zhang, H. Zhu, V. W. Yang and X. P. Zou, Reversal effects of pantoprazole on multidrug resistance in human gastric adenocarcinoma cells by down-regulating the V-ATPases/mTOR/HIF-1a/P-gp and MRP1 signaling pathway in vitro and in vivo, J. Cell. Biochem.113 (2012) 2474–2487; https://doi.org/10.1002/jcb.2412210.1002/jcb.24122
- 20. S. K. Bardaweel, H. A. Alsalamat, S. M. Aleidi and R. M. Bashatwah, Glucose deprivation enhances the antiproliferative effects of oral hypoglycemic biguanides in different molecular sub-types of breast cancer: An in vitro study, Acta Pharm.68 (2018) 517–524; https://doi.org/10.2478/acph-2018-003110.2478/acph-2018-0031
- 21. T. C. Chou, Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies, Pharmacol. Rev.58 (2006) 621–681; https://doi.org/10.1124/pr.58.3.1010.1124/pr.58.3.10
- 22. S. R. Sennoune, K. Bakunts, G. M. Martínez, J. L. Chua-Tuan, Y. Kebir, M. N Attaya and R. Martínez-Zaguilán, Vacuolar H+-ATPase in human breast cancer cells with distinct metastatic potential: distribution and functional activity, Am. J. Physiol. Cell Physiol.286 (2004) C1443-C1452; https://doi.org/10.1152/ajpcell.00407.200310.1152/ajpcell.00407.2003
- 23. J. Capecci and M. Forgac, The function of vacuolar ATPase (V-ATPase) a subunit isoforms in invasiveness of MCF10a and MCF10CA1a human breast cancer cells, J. Biol. Chem.288 (2013) 32731–32741; https://doi.org/10.1074/jbc.M113.50377110.1074/jbc.M113.503771
- 24. E. Iessi, M. Logozzi, D. Mizzoni, R. Di Raimo, C. Supuran and S. Fais, Rethinking the combination of proton exchanger inhibitors in cancer therapy, Metabolites8 (2018) 2; https://doi.org/10.3390/metabo801000210.3390/metabo8010002
- 25. A. De Milito, E. Iessi, M. Logozzi, F. Lozupone, M. Spada, M. L. Marino, C. Federici, M. Perdicchio, P. Matarrese, L. Lugini, A. Nilsson and S. Fais, Proton pump inhibitors induce apoptosis of human B-cell tumors through a caspase-independent mechanism involving reactive oxygen species, Cancer Res.67 (2007) 5408–5417; https://doi.org/10.1158/0008-5472.CAN-06-409510.1158/0008-5472.CAN-06-4095
- 26. L. Scaringi, P. Cornacchione, E. Ayroldi, L. Corazzi, E. Capodicasa, R. Rossi and P. Marconi, Omeprazole Induces apoptosis in jurkat cells, Int. J. Immunopathol. Pharmacol.17 (2004) 331–342; https://doi.org/10.1177/03946320040170031310.1177/039463200401700313
- 27. S. Zhang, Y. Wang and S. J. Li, Lansoprazole induces apoptosis of breast cancer cells through inhibition of intracellular proton extrusion, Biochem. Biophys. Res. Commun. 448 (2014) 424–429; https://doi.org/10.1016/j.bbrc.2014.04.12710.1016/j.bbrc.2014.04.127
- 28. C. Cristina, X. S. Renato, C. Susana, C. Sonia, J. O. Paulo, S. S. Maria and I. M. Paula, Doxorubicin: the good, the bad and the ugly effect, Curr. Med. Chem.16 (2009) 3267–3285; https://doi.org/10.2174/09298670978880331210.2174/092986709788803312
- 29. K. J. Patel, C. Lee, Q. Tan and I. F. Tannock, Use of the proton pump inhibitor pantoprazole to modify the distribution and activity of doxorubicin: a potential strategy to improve the therapy of solid tumors, Clin. Cancer Res.19 (2013) 6766–6776; https://doi.org/10.1158/1078-0432.CCR-13-012810.1158/1078-0432.CCR-13-0128
- 30. J. R. Rey, E. V. Cervino, M. L. Rentero, E. C. Crespo, A. O. Álvaro and M. Casillas, Raloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice, Open Orthop. J.3 (2009) 14–21; https://doi.org/10.2174/187432500090301001410.2174/1874325000903010014